Decision-making using absolute cardiovascular risk reduction and incremental cost-effectiveness ratios: A case study

Cardiovascular Journal of Africa

Volumn 19, Issue 2, 2008, Pages 97-101

  Ker, J A ^a   Oosthuizen, H ^b   Rheeder, P ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Sanofi Aventis

^c STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BEZAFIBRATE; INDAPAMIDE; PERINDOPRIL; STATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG COST; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MONOTHERAPY; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; DRUG THERAPY, COMBINATION; HEALTH STATUS INDICATORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 45349105516     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Norman R, Bradshaw D, Scheider M, Joubert J, Groenewald P, Lewin S, et al. A comparative risk assessment for South Africa in 2000: Towards promoting health and preventing disease. S Afr Med J 2007; 97: 637-641.
2. Ntyintyane LM, Panz VR, Gill GV. Metabolic syndrome, undiagnosed diabetes mellitus and insulin resistance are highly prevalent in urbanized South African blacks with coronary artery disease. Cardiovasc J South Afr 2006; 17(2): 50.
3. Blood pressure lowering treatment treatment trialist's collaboration. Effects of ACE-inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1906-1964.
4. Cheung BM, Launder U, Lau CP, Kumana CR. Meta analysis of large randomised controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640-651.
5. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease; a systematic review. J Am Med Assoc 2003; 290: 86-97.
6. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodger A. Treating individuals 5: Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365: 434-441.
7. Jackson R. Updated New Zealand cardiovascular disease risk benefit prediction guide. Br Med J 2000; 320: 709-710.
8. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, de Backer G, de Bacquer D, et al. Estimation of 10 year risk of fatal cardiovascular disease in Europe: the Score project. Eur Heart J 2003; 24: 987-1003.
9. Wilson PWF, D'Agostino RB, Ralph B, Levy D, Belanger A, Silbershatz H, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
10. Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. Br Med J 1997; 314: 1666-1674.
11. Grauer DW, Lee J, Odom TD (eds). Pharmacoeconomics and Outcomes: Applications for Patient Care, 2nd edn. Kansas City: American College of Clinical Pharmacy, 2003.
12. Joint National Hypertension Guideline Working Group. South African Hypertension Guideline 2006. S Afr Med J 2006; 96: 337-336.
13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and treatment of high blood cholesterol in adults (Adult treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
14. PROGRESS Collaborative Group effects of a perindropil-based blood pressure lowering regimen on cardiac out comes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475-484.
15. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the Efficacy and safety of Rosuvastatin Versus atorvastatin and Pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-160.
16. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of Olmesartan medoxomil compared with Amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425-432.
17. Birjmohun RS, Hutten BA, Kasselein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-197.
18. Quaglini S, Stefanelli M, Boiocchi L, Compari F, Cavallini A, Micieli G. Cardiovascular risk calculators: understanding differences and realising economic implications. Int J Med Inf 2005; 74: 191-199.
19. El Fakiri F, Bruijnzeels MH, Hoes AW. Prevention of cardiovascular disease: focus on modifiable cardiovascular risk. Heart 2006; 92: 741-745.
20. Campbell NRC, Khan NA, Grover SA. Barriers and remaining questions on assessment of absolute cardiovascular risk as a starting point for interventions to reduce cardiovascular risk. J Hypertens 2006; 24: 1683-1685.
21. Vogel JA, Franklin BA, Kersteyn C, Zalestin JE, Krause KR, Chengelis DL, et al. Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery. Am J Cardiol 2007; 99: 222-226.